CAR T and Other Options for Relapsed/Refractory Follicular Lymphoma: Javier L. Munoz, MD, MS, FACP

Video

The director of Mayo Clinic's Lymphoma Program discussed R/R FL and current treatment options.

This content originally appeared on our sister site, CancerNetwork.

Recent Videos
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – January 17, 2025

CGTLive Staff
January 17th 2025
Article

Review top news and interview highlights from the week ending January 17, 2025.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD

FDA Issues CRL for Atara Biotherapeutics’ BLA for T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD

Noah Stansfield
January 16th 2025
Article

The CRL was related inspection of a third-party manufacturer rather than any efficacy or safety concerns regarding the product itself.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Transplant Eligibility Versus CAR-T Eligibility

Manali Kamdar, MD;Noah Stansfield
January 16th 2025
Article

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025

Noah Stansfield
January 15th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Sequencing of Treatment in Third-Line R/R LBCL

Manali Kamdar, MD;Noah Stansfield
January 15th 2025
Article

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.

© 2025 MJH Life Sciences

All rights reserved.